Wednesday August 12, 2020

CF drug maker offers treatment at surcharge of €23,000 per patient

Cystic Fibrosis Ireland boss says ‘no justification for price differential’ with Britain

Susan Mitchell

Deputy Editor and Health Editor

@susmitchellsbp
26th June, 2016
Cystic Fibrosis drug called Orkambi

The manufacturer of the breakthrough Cystic Fibrosis drug called Orkambi proposed charging €23,000 more per person for its drug in Ireland compared with England.

Vertex offered a €158,000 price tag per patient per year to the Irish health service in the submission it made a few months ago.

Vertex then offered England’s National Health Service (NHS) a list price of €135,000 (£104,000) per patient per year.

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Irish doctors will not use the term ‘fully reversible’ in future, following a change in Britain’s NHS guidance on hormone treatment for transgender children

Aaron Rogan | 3 days ago

The founder of the expert group EndCoronavirus says New Zealand’s zero tolerance model is the only option against the virus

Rachel Lavin | 3 days ago

Unicef adviser says ‘special effort’ must be made to catch children up on immunisations missed due to Covid-19

Rachel Lavin | 3 days ago